You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020233017
Dec 20205106
Jan 20216808
Feb 202149011
Mar 202173011
Apr 202196012
May 20211809
Jun 20212016
Jul 2021109
Aug 20210011
Sep 20210013
Oct 202170025
Nov 2021175022
Dec 202110303
Jan 20225809
Feb 20229408
Mar 2022132013
Apr 2022138029
May 2022134016
Jun 20229407
Jul 202298010
Aug 2022118013
Sep 20229408
Oct 2022150014
Nov 2022166010
Dec 20226607
Jan 2023142025
Feb 202394019
Mar 2023150017
Apr 202311008
May 20238409
Jun 202368010
Jul 2023108012
Aug 202392014
Sep 202312008
Oct 2023112015
Nov 20239603
Dec 20237404
Jan 20243803
Feb 20244001
Mar 202410807
Apr 20245006
May 20245602
Jun 20246303
Jul 202464013
Aug 202463016
Sep 20244605
Oct 20248608
Nov 20244206
Dec 202454010
Jan 20256808
Feb 2025806
Mar 2025001
Apr 2025004
May 2025003
Jun 20250010
Total43170573